Which of of patients with type 2 diabetes.

This allows Phosphagenics to begin the next phase of the clinical development program for TPM / Insulin at the Joslin Diabetes Center. It is expected that the U.S. Portion of the study will begin later this year. – ‘We have collected the appropriate positive data for our Phase 2 trial for the treatment of patients with type 1 diabetes, the ideal patient population to demonstrate the efficacy of our TPM / Insulin is progress,’said Dr. Esra Ogru, Executive Vice President of research and Development at Phosphagenics. ‘The Australian clinical trials have so far shown Dr. TPM can / insulin formulation safely penetrate through human skin and deliver insulin into the bloodstream over a prolonged period without side effects ‘..

An ADR – Level 1 program was in the U.S. With The Bank of New York Mellon established for U.S. Investors to trade in Phosphagenics ‘ stock on the ‘ over-the-counter market. In July 2007, these. To the International OTCQX, a new premium market animals in the U.S. For international listed companies, the upgraded operated by Pink Sheets, LLC.. Phosphagenics ‘ core technology is the science and application of phosphorylation, a process in which the addition of a phosphate group has been found to enhance the bioavailability, efficacy and safety of existing pharmaceuticals and nutraceuticals, as well as built in support of the production of drug delivery platforms. In July 2007agenics ‘ shares are listed on the Australian Stock Exchange and the London Stock Exchange Alternative Investment Market .We ask the Commission to ensure that patient safety over any other reflection where preparing legislation over health.

The nurses and Obstetrics Council , which regulator for all nursing and midwifery the UK, which adoption of the EU Directive has responded the application of patients rights reserved ‘. ‘rights in cross border healthcare of draft directive clarifying the circumstances in which the EU in the EU, are reimbursed applied requested with their home for health care into in another Member State.